A non-functional 5′ ALK fusion validated at the RNA level as a classical EML4-ALK that responds well to the novel ALK inhibitor ensartinib: A case report

A non-functional 5′ ALK fusion validated at the RNA level as a classical EML4-ALK that responds well to the novel ALK inhibitor ensartinib: A case report

BackgroundCurrently, many targeted drugs are approved for treatment of ALK fusion non-small cell lung cancer. However, it has been previously assumed that patients with 5′ non-oncogenic kinase (5′ NOK) fusion detected by DNA next-generation sequencing (NGS) would not benefit from ALK inhibitors beca...

Full description

Bibliographic Details
Main Authors: Hong Yang, Haojing Li, Yu Fang, Zhijun Li, Jianhua Zhu, Huan Liu, Chao Lu, Xiaoyan Zhang, Tonghui Ma, Cuiying Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Medicine
Subjects:
5′ NOK fusion
ALK
RNA NGS
ensartinib
NSCLC
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.979032/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.979032/full

Similar Items